Skip to main content

Table 1 Characteristics of patients in PF group and TPF group before and after propensity score matching analysis

From: Survival outcomes of adjuvant taxanes, platinum plus fluoropyrimidines versus platinum and fluoropyrimidines for gastric cancer patients after D2 gastrectomy: a retrospective propensity score-matched analysis

  Before PSM After PSM
Variables PF group
[n (%), n = 425]
TPF group
[n (%), n = 177]
X2/Z P PF group
[n (%), n = 172]
TPF group
[n (%), n = 172]
X2/Z P
Age (years) [median (IQR)] 61 (52~67) 58 (48~63) −4.017a <0.001 60 (51~64) 58 (48~63) −1.399a 0.162
 < 65 271 (63.8) 141 (79.7) 14.618 < 0.001 130 (75.6) 136 (79.1) 0.597 0.440
 65~ 154 (36.2) 36 (20.3) 42 (24.4) 36 (20.9)
Sex    0.383 0.536    0.234 0.628
 Male 313 (73.6) 126 (71.2)    127 (73.8) 123 (71.5)   
 Female 112 (26.4) 51 (28.8)    45 (26.2) 49 (28.5)   
Tumor location    2.348 0.125    0.187 0.665
 Cardia 214 (50.4) 77 (43.5)    81 (47.1) 77 (44.8)   
 Non-cardia 211 (49.6) 100 (56.5)    91 (52.9) 95 (55.2)   
Borrmann subtype    0.760 0.944    2.785 0.594
 I 13 (3.1) 5 (2.8)    7 (4.1) 5 (2.9)   
 II 125 (29.4) 57 (32.2)    46 (26.7) 57 (33.1)   
 III 241 (56.7) 94 (53.1)    101 (58.7) 90 (52.3)   
 IV 26 (6.1) 12 (6.8)    12 (7.0) 11 (6.4)   
 Unknown 20 (4.7) 9 (5.1)    6 (3.5) 9 (5.2)   
Grade    1.452 0.484    1.356 0.508
 G1-2 111 (26.1) 38 (21.5)    41 (23.8) 37 (21.5)   
 G3-4 285 (67.2) 126 (71.2)    113 (65.7) 122 (70.9)   
 Unknown 29 (6.8) 13 (7.3)    18 (10.5) 13 (7.6)   
T stage (AJCC 7th)    2.315 0.510    0.062 0.996
 T1 13 (3.1) 10 (5.6)    10 (5.8) 9 (5.2)   
 T2 26 (6.1) 10 (5.6)    10 (5.8) 10 (5.8)   
 T3 244 (57.4) 100 (56.5)    97 (56.4) 97 (56.4)   
 T4 142 (33.4) 57 (32.2)    55 (32.0) 56 (32.6)   
N stage (AJCC 7th)    4.149 0.246    2.971 0.396
 N0 86 (20.2) 25 (14.1)    33 (19.2) 25 (14.5)   
 N1 80 (18.8) 42 (23.7)    30 (17.4) 41 (23.8)   
 N2 113 (26.6) 50 (28.2)    54 (31.4) 50 (29.1)   
 N3 146 (34.4) 60 (33.9)    55 (32.0) 56 (32.6)   
Stage (AJCC 7th)    3.840 0.147    0.528 0.768
 I 17 (4.0) 12 (6.8)    11 (6.4) 11 (6.4)   
 II 137 (32.2) 46 (26.0)    52 (30.2) 46 (26.7)   
 III 271 (63.8) 119 (67.2)    109 (63.4) 115 (66.9)   
Vascular invasion    1.899 0.168    0.134 0.714
 Yes 102 (24.0) 52 (29.4)    44 (25.6) 47 (27.3)   
 No 323 (76.0) 125 (70.6)    128 (74.4) 125 (72.7)   
Perineural invasion    0.001 0.979    0.091 0.763
 Yes 70 (16.5) 29 (16.4)    25 (14.5) 27 (15.7)   
 No 355 (83.5) 148 (83.6)    147 (85.5) 145 (84.3)   
Tumor deposits    1.546 0.214    0.595 0.441
 Positive 47 (11.1) 26 (14.7)    27 (15.7) 22 (12.8)   
 Negative 378 (88.9) 151 (85.3)    145 (84.3) 150 (87.2)   
Laparotomic approaches    0.454 0.500    0.000 1.000
 Open 384 (90.4) 163 (92.1)    158 (91.9) 158 (91.9)   
 Laporascopy 41 (9.6) 14 (7.9)    14 (8.1) 14 (8.1)   
Scope of gastrectomy    1.451 0.228    0.212 0.645
 Total gastrectomy 302 (71.1) 117 (66.1)    118 (68.6) 114 (66.3)   
 Partial gastrectomy 123 (28.9) 60 (33.9)    54 (31.4) 58 (33.7)   
 Hemoglobin (g/L) [median (IQR)] 111 (98~121) 115 (102~123) 1.647a 0.100 111 (98~120) 114 (102~123) 1.565a 0.118
 Albumin (g/L) [median (IQR)] 38.6 (35.6~41.9) 39.3 (36.0~42.7) 1.059a 0.290 38.0 (34.3~41.6) 39.2 (36.0~42.6) 1.776a 0.076
  1. aIndependent-samples Mann-Whitney U test
  2. PF, platinum plus fluoropyrimidines; TPF, taxanes, platinum plus fluoropyrimidines; PSM, propensity score matching analysis; IQR, inter quartile range. AJCC 7th, the seventh edition of cancer staging system by the American Joint Committee on Cancer